

Chul-Won Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3847717/publications.pdf>

Version: 2024-02-01

168
papers

2,666
citations

236833

25
h-index

233338

45
g-index

169
all docs

169
docs citations

169
times ranked

3876
citing authors

#	ARTICLE	IF	CITATIONS
1	Composite follicular lymphoma and classic Hodgkin lymphoma. <i>Journal of Pathology and Translational Medicine</i> , 2022, 56, 57-60.	0.4	3
2	Peripheral T cell lymphoma of the nasopharynx with expansion of EBV-positive B cells masquerading as an extranodal NK/T cell lymphoma, nasal type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, , 1.	1.4	0
3	Postoperative Thromboembolism According to the Type of Surgery: A Nationwide Study in the Republic of Korea. <i>Journal of Clinical Medicine</i> , 2022, 11, 1477.	1.0	1
4	How myeloproliferative neoplasms patientsâ€™ experience and expectations differ from physiciansâ€™: the international MPN Landmark survey. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 444-454.	0.7	2
5	Total Platelet Transcriptomics and Its Network Analysis by RNA-Seq and miRNA-Seq and PCA Application in Essential Thrombocythaemia. <i>Acta Haematologica</i> , 2021, 144, 337-344.	0.7	1
6	Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S196-S206.	0.7	9
7	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	1.0	2
8	Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 687361.	1.3	0
9	Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1261-1280.	0.7	3
10	A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea. <i>Scientific Reports</i> , 2021, 11, 18449.	1.6	3
11	The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 45-62.	0.7	13
12	The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1459-1470.	0.7	0
13	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWPâ€164) Tj ETQq1 1 @.784314 ogBT /Ov		
14	Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. <i>Scientific Reports</i> , 2020, 10, 39.	1.6	13
15	Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096688.	1.1	2
16	Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with nonâ€Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. <i>Transplant International</i> , 2020, 33, 1211-1219.	0.8	3
17	Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab. <i>Annals of Hematology</i> , 2020, 99, 1493-1503.	0.8	2
18	Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim. <i>Cancer Medicine</i> , 2020, 9, 6102-6110.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). <i>British Journal of Haematology</i> , 2020, 189, 303-312.	1.2	21
20	Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 970-978.	0.7	6
21	The role of platelet function analyzer-200 in predicting perioperative bleeding risk. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1199-1209.	0.7	7
22	Recent insights regarding the molecular basis of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1-11.	0.7	25
23	Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2019, 34, 579-588.	0.7	9
24	Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 656-664.	0.2	5
25	Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2019, 186, e151-e155.	1.2	2
26	Hereditary platelet function disorder from <i>RASGRP2</i> gene mutations encoding CalDAG-GEFI identified by whole-exome sequencing in a Korean woman with severe bleeding. <i>Haematologica</i> , 2019, 104, e274-e276.	1.7	9
27	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 92-95.	0.6	10
28	Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1333-1346.	0.7	3
29	Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab. <i>Blood</i> , 2019, 134, 2227-2227.	0.6	1
30	The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. <i>Acta Haematologica</i> , 2018, 140, 146-156.	0.7	13
31	The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker. <i>Anticancer Research</i> , 2018, 38, 3935-3942.	0.5	19
32	Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. <i>PLoS ONE</i> , 2018, 13, e0192656.	1.1	2
33	Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFR α rearrangement: full recovery with low dose imatinib. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 642-644.	0.7	3
34	One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea. <i>Blood</i> , 2018, 132, 3347-3347.	0.6	0
35	Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. <i>Leukemia Research</i> , 2017, 57, 1-8.	0.4	6
36	Quality assurance for a multicenter Phase II study of stereotactic ablative radiotherapy for hepatocellular carcinoma \leq 5 cm: a planning dummy run. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 535-542.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 7180-7188.	3.2	57
38	Long-term clinical outcomes of the single-incision technique for implantation of implantable venous access ports via the axillary vein. <i>Journal of Vascular Access</i> , 2017, 18, 345-351.	0.5	10
39	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. <i>Blood Research</i> , 2017, 52, 207.	0.5	11
40	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , 2017, 8, 37605-37618.	0.8	6
41	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	0.8	16
42	Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 711-721.	0.7	19
43	Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 722-730.	0.7	7
44	A Case of Acquired Factor V Deficiency after Percutaneous Coronary Intervention. <i>Korean Journal of Medicine</i> , 2017, 92, 480-483.	0.1	0
45	Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. <i>Annals of Hematology</i> , 2016, 95, 337-344.	0.8	22
46	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	5.1	285
47	Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 357-366.	0.7	9
48	Advances in the Diagnosis of Myeloproliferative Neoplasms. <i>Korean Journal of Medicine</i> , 2016, 90, 281-287.	0.1	1
49	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	0.6	0
50	Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy. <i>Blood</i> , 2016, 128, 3041-3041.	0.6	0
51	Guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 771-788.	0.7	22
52	Selection of Elderly Acute Myeloid Leukemia Patients for Intensive Chemotherapy: Effectiveness of Intensive Chemotherapy and Subgroup Analysis. <i>Acta Haematologica</i> , 2015, 133, 300-309.	0.7	8
53	Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 914-920.	0.6	0
54	Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. <i>Annals of Hematology</i> , 2015, 94, 1485-1492.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage. <i>Acta Haematologica</i> , 2015, 134, 59-68.	0.7	5
56	Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 1687-1687.	0.6	1
57	Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial. <i>Blood</i> , 2015, 126, 476-476.	0.6	9
58	A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2015, 6, 44985-44994.	0.8	17
59	Dosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2015, 33, 233.	0.7	21
60	Novel Agents in the Treatment of Chronic Lymphocytic Leukemia. <i>Korean Journal of Medicine</i> , 2015, 88, 258.	0.1	0
61	Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib. <i>Blood</i> , 2015, 126, 4053-4053.	0.6	0
62	Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies. <i>Blood</i> , 2015, 126, 4889-4889.	0.6	0
63	Incidence and Risk Factors of Infectious Complications Related to Implantable Venous-Access Ports. <i>Korean Journal of Radiology</i> , 2014, 15, 494.	1.5	42
64	Case Report of Pulmonary Sarcoidosis Suspected to be Pulmonary Metastasis in a Patient with Breast Cancer. <i>Cancer Research and Treatment</i> , 2014, 46, 317-321.	1.3	13
65	A Rare Case of Polycythemia Vera Following Acute Undifferentiated Leukemia Remission. <i>Annals of Laboratory Medicine</i> , 2014, 34, 469-470.	1.2	5
66	The puzzle of myeloproliferative neoplasms: novel disease-specific mutations and new proposals for diagnostic criteria. <i>Blood Research</i> , 2014, 49, 211.	0.5	3
67	Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. <i>Haematologica</i> , 2014, 99, 1191-1196.	1.7	55
68	Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. <i>Annals of Hematology</i> , 2014, 93, 1571-1577.	0.8	3
69	Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 352.	0.7	27
70	Prevalence of and Factors Associated with Malignancy in Males with Iron-Deficiency Anemia. <i>Korean Journal of Medicine</i> , 2014, 87, 53.	0.1	1
71	Management of Polycythemia Vera and Essential Thrombocythemia. <i>Korean Journal of Medicine</i> , 2014, 86, 26.	0.1	0
72	Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2014, 124, 5151-5151.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Endovascular Management of Symptomatic Carotid Artery Stenosis in a Patient with Thrombocytopenia. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2013, 74, e62-e65.	0.4	0
74	BK virus encephalitis without concurrent hemorrhagic cystitis in an allogeneic hematopoietic stem cell transplant recipient. <i>Blood Research</i> , 2013, 48, 226.	0.5	9
75	Efficacy Of Ruxolitinib In Korean Myelofibrosis Patients and Cases Complicated TB Lymphadenitis During The Treatment. <i>Blood</i> , 2013, 122, 1596-1596.	0.6	11
76	High-Dose Cytarabine Consolidation (1.5 g/m ²) Might Have Shown a Better Outcomes Than Intermediate-Dose Cytarabine (1.0 g/m ²) Combined With Anthracyclines In AML Patients Who Had Achieved Complete Remissions In The First Induction by Standard 3+7 Regimen. <i>Blood</i> , 2013, 122, 2692-2692.	0.6	6
77	Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. <i>Blood</i> , 2013, 122, 3720-3720.	0.6	1
78	Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). <i>International Journal of Hematology</i> , 2012, 96, 631-637.	0.7	5
79	Effects of oral iron chelator deferasirox on human malignant lymphoma cells. <i>The Korean Journal of Hematology</i> , 2012, 47, 194.	0.7	16
80	Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. <i>International Journal of Cancer</i> , 2012, 131, 235-243.	2.3	47
81	A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2012, 44, 127-132.	1.3	9
82	Hepatic and Small Bowel Mucormycosis after Chemotherapy in a Patient with Acute Myeloid Leukemia: A Case Report and Literature Review. <i>Infection and Chemotherapy</i> , 2012, 44, 516.	1.0	0
83	Human Feeder Cells Can Support the Undifferentiated Growth of Human and Mouse Embryonic Stem Cells Using Their Own Basic Fibroblast Growth Factors. <i>Stem Cells and Development</i> , 2011, 20, 1901-1910.	1.1	26
84	Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). <i>BMC Cancer</i> , 2011, 11, 321.	1.1	107
85	A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. <i>Haematologica</i> , 2011, 96, 1441-1447.	1.7	58
86	Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. <i>Blood</i> , 2011, 117, 1958-1965.	0.6	121
87	Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. <i>Annals of Hematology</i> , 2011, 90, 539-546.	0.8	26
88	Successful control of steroid-intolerant Evans' syndrome associated with allogeneic peripheral blood hematopoietic stem cell transplant by rituximab. <i>Leukemia and Lymphoma</i> , 2011, 52, 528-530.	0.6	4
89	Pretreatment Serum Level of 15-kDa Granulysin Might Have a Prognostic Value in Patients with Diffuse Large B Cell Lymphoma. <i>Acta Haematologica</i> , 2011, 126, 79-86.	0.7	5
90	The Oral Iron Chelator Deferasirox Induces Apoptosis in Myeloid Leukemia Cells by Targeting Caspase. <i>Acta Haematologica</i> , 2011, 126, 241-245.	0.7	25

#	ARTICLE	IF	CITATIONS
91	First-Line Dasatinib Plus Conventional Chemotherapy in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Interim Analysis of the Korean Prospective Phase II Study. <i>Blood</i> , 2011, 118, 1516-1516.	0.6	7
92	Treatment Outcomes and Prognostic Factors of Ifosfamide, Etoposide, Cytarabine, Methotrexate, and Dexamethasone (IVAMdex) Regimen As 3rd Line (2nd salvage) Chemotherapy in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 2685-2685.	0.6	0
93	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. <i>Blood</i> , 2011, 118, 1866-1866.	0.6	0
94	Busulfan, Melphalan and Etoposide Followed by Autologous Stem Cell Transplantation on Patients with Non-Hodgkin's Lymphoma: Multicenter Study From Consortium for Improving Survival of Lymphoma (CISL) in Korea. <i>Blood</i> , 2011, 118, 2021-2021.	0.6	0
95	Pulmonary marginal zone B-cell lymphoma of MALT type: What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study. <i>Annals of Hematology</i> , 2010, 89, 563-568.	0.8	54
96	Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. <i>International Journal of Hematology</i> , 2010, 92, 510-517.	0.7	13
97	Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. <i>BMC Cancer</i> , 2010, 10, 321.	1.1	73
98	Acute myeloid leukemia (AML-M2) associated with variant t(8;21): report of three cases. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 31-37.	1.0	13
99	Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2010, 102, 209-214.	0.8	128
100	The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. <i>Leukemia Research</i> , 2010, 34, 294-300.	0.4	24
101	Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. <i>Leukemia Research</i> , 2010, 34, 1175-1179.	0.4	24
102	Stage IV marginal zone B-cell lymphoma: prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Cancer Science</i> , 2010, 101, 2443-2447.	1.7	8
103	Efficacy and Safety of Micafungin as an Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases. <i>Acta Haematologica</i> , 2010, 124, 92-97.	0.7	16
104	Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma In Patients Treated with R-Chop; Consortium for Improving Survival of Lymphoma (CISL) Study.. <i>Blood</i> , 2010, 116, 1790-1790.	0.6	1
105	Intensified 1st Cycle Rituximab (R) Plus 8th Cycles of R-CHOP (cyclophosphamide, adriamycin, Tj ETQq1 1 0.784314 rgBT /Overlock 10 B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis.. <i>Blood</i> , 2010, 116, 1786-1786.	0.6	0
106	Waldeyer's Ring Marginal Zone B-Cell Lymphoma: Which Is Their Clinical and Prognostic Feature, Nodal or Extranodal?. <i>Blood</i> , 2010, 116, 5084-5084.	0.6	0
107	Pretreatment Serum Level of 15-KDa Granulysin Might Predict Recurrence and Survival of Diffuse Large B Cell Lymphoma Patients Treated by R-CHOP Regimen. <i>Blood</i> , 2010, 116, 1993-1993.	0.6	0
108	ANUP98-HOXD13 Fusion Gene Impairs Differentiation of B and T Lymphocytes and Leads to Expansion of Thymocytes with Partial TCRB Gene Rearrangement. <i>Journal of Immunology</i> , 2009, 183, 6227-6235.	0.4	23

#	ARTICLE	IF	CITATIONS
109	Cytogenetic abnormality involving 8p11.2 in T-lymphoblastic lymphoma: report of a new case. <i>Cancer Genetics and Cytogenetics</i> , 2009, 191, 57-58.	1.0	6
110	A novel cytogenetic abnormality in primary myelofibrosis. <i>Cancer Genetics and Cytogenetics</i> , 2009, 194, 65-66.	1.0	0
111	Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases. <i>American Journal of Hematology</i> , 2009, 84, 826-829.	2.0	10
112	Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 433-439.	1.1	14
113	Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. <i>Leukemia and Lymphoma</i> , 2009, 50, 1119-1125.	0.6	21
114	Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , 2009, 114, 1792-1792.	0.6	1
115	Reversible Posterior Leukoencephalopathy Syndrome in a Patient with Relapsed Hodgkin's Disease: A Case Report. <i>The Korean Journal of Hematology</i> , 2009, 44, 177.	0.7	0
116	Changes in Serum Protein Profiles During Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT): Clinical Significance of Serum C-Reactive Protein and Haptoglobin Levels.. <i>Blood</i> , 2009, 114, 4658-4658.	0.6	0
117	Clinical Features and Prognostic Relevance of Ovarian Involvement in Non-Hodgkin's Lymphoma: a Consortium for Improving Survival of Lymphoma (CISL) Report.. <i>Blood</i> , 2009, 114, 4999-4999.	0.6	0
118	Effects of Reduced Dose of Imatinib to Korean Chronic Myeloid Leukemia in Chronic Phase.. <i>Blood</i> , 2009, 114, 4290-4290.	0.6	0
119	Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.. <i>Blood</i> , 2009, 114, 4661-4661.	0.6	0
120	Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. <i>Blood</i> , 2009, 114, 5017-5017.	0.6	0
121	Treatment Outcome and Quality of Life in Non-Hodgkin's Lymphoma of Intestine: a Multicenter Study of the Consortium for Improving Survival of Lymphoma (CISL).. <i>Blood</i> , 2009, 114, 4992-4992.	0.6	0
122	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea.. <i>Blood</i> , 2009, 114, 5024-5024.	0.6	7
123	Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NF- κ B and Bcl-XL. <i>Investigational New Drugs</i> , 2008, 26, 277-282.	1.2	3
124	Increased Serum 90K and Galectin-3 Expression Are Associated with Advanced Stage and a Worse Prognosis in Diffuse Large B-Cell Lymphomas. <i>Acta Haematologica</i> , 2008, 120, 211-216.	0.7	35
125	Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. <i>European Journal of Haematology</i> , 2008, 81, 177-184.	1.1	30
126	Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 14088-14093.	3.3	37

#	ARTICLE	IF	CITATIONS
127	Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome. <i>Haematologica</i> , 2008, 93, 1394-1397.	1.7	22
128	Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. <i>Annals of Oncology</i> , 2007, 18, 1382-1387.	0.6	90
129	Telomere Length Shortening of Peripheral Blood Mononuclear Cells in Solid-Cancer Patients Undergoing Standard-Dose Chemotherapy Might Be Correlated with Good Treatment Response and Neutropenia Severity. <i>Acta Haematologica</i> , 2007, 118, 30-37.	0.7	17
130	Reduced Dose of Imatinib for Patients with Chronic Myeloid Leukemia and Low Body Surface Area. <i>Acta Haematologica</i> , 2007, 118, 219-221.	0.7	22
131	Persistent Anemia in a Patient with Diffuse Large B Cell Lymphoma: Pure Red Cell Aplasia Associated with Latent Epstein-Barr Virus Infection in Bone Marrow. <i>Journal of Korean Medical Science</i> , 2007, 22, S167.	1.1	7
132	Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer. <i>Medical Oncology</i> , 2007, 24, 33-37.	1.2	3
133	Treatment Outcomes and Toxicities of ABVD Combination Chemotherapy Compared with CVPP in Hodgkin's Disease. <i>The Korean Journal of Hematology</i> , 2007, 42, 335.	0.7	0
134	A NUP98-HOXD13 Fusion Gene Impairs Differentiation of T and B Lymphocytes.. <i>Blood</i> , 2007, 110, 2650-2650.	0.6	6
135	Serum B-Cell Activating Factor (BAFF) in Diffuse Large B-Cell Lymphoma: Its Prognostic Significance in the Rituximab Era.. <i>Blood</i> , 2007, 110, 1575-1575.	0.6	0
136	Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. <i>Leukemia and Lymphoma</i> , 2006, 47, 1265-1273.	0.6	42
137	Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. <i>British Journal of Haematology</i> , 2006, 134, 45-53.	1.2	22
138	uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. <i>Cell Research</i> , 2006, 16, 75-81.	5.7	26
139	Acute arthritis of carpal bones secondary to metastatic gastric cancer. <i>Clinical Rheumatology</i> , 2006, 25, 258-261.	1.0	8
140	Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 436-442.	1.1	19
141	Mesenchymal Stem Cells Derived from Human Chorionic Plate May Promote Hematopoietic Differentiation of the Human Embryonic Stem Cell Line SNUhES3. <i>Acta Haematologica</i> , 2006, 116, 219-222.	0.7	5
142	Detection of Extracellular Protein Kinase A (ECPKA) Autoantibody in Non-Hodgkin's Lymphoma: Its Increased Antibody Titer Decreases with a Favorable Treatment Response.. <i>Blood</i> , 2006, 108, 4621-4621.	0.6	1
143	Prognostic Significance of Ki-67 Expression in Extranodal NK/T Cell Lymphoma, Nasal Type: A Proposed Prognostic Index, KLABS Index.. <i>Blood</i> , 2006, 108, 2055-2055.	0.6	2
144	Follow-up Study of Peripheral Blood Carcinoembryonic Antigen mRNA Using Reverse Transcription-Polymerase Chain Reaction as an Early Marker of Clinical Recurrence in Patients With Curatively Resected Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 24-29.	0.6	23

#	ARTICLE	IF	CITATIONS
145	Incidence of anemia in older Koreans: Community-based cohort study. Archives of Gerontology and Geriatrics, 2005, 41, 303-309.	1.4	8
146	The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. Cancer, 2005, 103, 2338-2343.	2.0	12
147	The cutoff value of serum ferritin for the diagnosis of iron deficiency in community-residing older persons. Annals of Hematology, 2005, 84, 358-361.	0.8	24
148	Hematopoietic Differentiation of Embryoid Bodies Derived from the Human Embryonic Stem Cell Line SNUhES3 in Co-culture with Human Bone Marrow Stromal Cells. Yonsei Medical Journal, 2005, 46, 693.	0.9	18
149	Prevalence of Iron Deficiency Anemia in Community-Dwelling Older Persons as Measured by the Transferrin Receptor-Ferritin Index. Acta Haematologica, 2005, 114, 180-182.	0.7	2
150	Autocrine Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2 Growth Pathway Represents a Cyclooxygenase-2-Independent Target for the Cyclooxygenase-2 Inhibitor NS-398 in Colon Cancer Cells. Oncology, 2005, 68, 204-211.	0.9	15
151	The Feasibility of High-Dose Dexamethasone (HD-DEX) in Idiopathic Thrombocytopenic Purpura (ITP) in Adults; a Multi-Center Study in Korea.. Blood, 2005, 106, 4009-4009.	0.6	4
152	Prediction of Survival in Patients with Non-Hodgkin's Lymphoma: Role of Tumor Necrosis Factor Ligand-Receptor and Extracellular Protein Kinase A.. Blood, 2005, 106, 4737-4737.	0.6	0
153	Treatment Outcome of Localized Extranodal NK/T Cell Lymphoma in Nasal and Upper Aerodigestive Tract: A Single Institute Experience in Korea.. Blood, 2005, 106, 2682-2682.	0.6	0
154	Serum Vascular Endothelial Growth Factor per Platelet Count in Hepatocellular Carcinoma: Correlations with Clinical Parameters and Survival. Japanese Journal of Clinical Oncology, 2004, 34, 184-190.	0.6	53
155	NK/T-Cell Lymphoma Associated with Epstein-Barr Virus in a Patient Infected with Human Immunodeficiency Virus: An Autopsy Case. International Journal of Hematology, 2004, 79, 480-483.	0.7	6
156	Prevalence and characteristics of anemia in the elderly: Cross-sectional study of three urban Korean population samples. American Journal of Hematology, 2004, 77, 26-30.	2.0	42
157	Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report. American Journal of Hematology, 2004, 77, 366-369.	2.0	14
158	The Cutoff Value of Serum Ferritin for the Diagnosis of Iron Deficiency in the Community-Residing Older Persons.. Blood, 2004, 104, 5291-5291.	0.6	0
159	The Effect of Telomerase Antisense for the Differentiation of Embryonic Stem Cells to Hemopoietic Stem Cells.. Blood, 2004, 104, 4201-4201.	0.6	0
160	Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. American Journal of Hematology, 2003, 73, 263-266.	2.0	35
161	Unusual Presentation of Thymic Carcinoma : Hypertrophic Osteoarthropathy. Korean Journal of Internal Medicine, 2003, 18, 125-128.	0.7	3
162	ESHAP Salvage Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma. Journal of Korean Medical Science, 2002, 17, 621.	1.1	14

#	ARTICLE	IF	CITATIONS
163	Autologous Peripheral Blood Stem Cell Transplantation Using G-CSF Combined Conditioning in AML Patients. <i>Immune Network</i> , 2002, 2, 49.	1.6	0
164	Long-Term Engraftment Stability of Peripheral Blood Stem Cells Cryopreserved Using the Dump-Freezing Method in a -80°C Mechanical Freezer with 10% Dimethyl Sulfoxide. <i>International Journal of Hematology</i> , 2001, 73, 245-250.	0.7	25
165	Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. <i>American Journal of Hematology</i> , 2001, 66, 197-202.	2.0	35
166	Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. <i>American Journal of Hematology</i> , 2001, 66, 197-202.	2.0	1
167	The healing effect of rhGM-CSF on uninfected wounds. <i>Immune Network</i> , 2001, 1, 32.	1.6	0
168	Effects of 5-Fluorouracil and Leucovorin in the Treatment of Pancreatic Biliary Tract Adenocarcinomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 425-428.	0.6	110